Modern advances in the development of neurotropic drugs

Among the drugs that prevent the development of mental illness, the consequences of epilepsy and cerebral palsy, the use of neurotropic drugs in various dosage forms (DF) is considered promising and expedient [1, 4–9, 18]. Over the past 10-15 years, a large number of publications have been accumulated on the achievements in the development of highly active neurotropic drugs, which served as an impetus for the study of their pharmacological activity and mechanism of action. Nevertheless, among specialists involved in the search and development of nootropics, there is no single point of view regarding the classification of this group of drugs, which makes it very difficult to assess the drug market [5]. So, along with antidepressants, tranquilizers, anxiolytics and neuroleptics, in France, nootropics are referred to as psychotropic drugs, in Japan - to CNS stimulants, in Italy - to analeptics [6]. About 60 leading pharmaceutical companies in various countries of the world are engaged in the search and research of nootropic drugs [6].